FIELD: medicine; pharmaceutics.
SUBSTANCE: present invention relates to an intranasal composition for preventing and/or treating infectious-inflammatory diseases of the nasal cavity, caused by influenza A virus or human coronavirus OC43 or bacteria S. epidermidis, S. aureus, A. baumannii, K. pneumoniae, E. coli or P. aeruginosa, containing high molecular weight hyaluronic acid, high molecular weight polyvinylpyrrolidone (high molecular weight PVP), poviargol, an antibacterial polypeptide, which is gramidine C or lysozyme, sodium hypochlorite solution, gelofusine, with the following ratio of components, wt.%: high molecular weight hyaluronic acid—0.1–2.0; high-molecular weight PVP—4.0–6.0; poviargol—0.8–1.2; antibacterial polypeptide gramicidin C—0.03–0.15 or lysozyme—0.1–18.0; sodium hypochlorite solution—49.0–51.0; gelofusine up to 100.0, also relates to the use of an intranasal composition for preventing and/or treating infectious-inflammatory diseases of the nasal cavity, caused by influenza A virus or human coronavirus OC43 or bacteria S. epidermidis, S. aureus, A. baumannii, K. pneumoniae, E. coli or P. aeruginosa coronaviruses, influenza virus, other RNA- and DNA-containing viruses and bacteria, accompanied by the formation of microbial biofilms, where the composition is applied on the nasal mucosa once a day.
EFFECT: present invention provides a more effective composition of a wide spectrum of action compared to the prototype for the prevention and/or complex treatment of infectious-inflammatory diseases of the nasal cavity with intranasal application, having prolonged broad antimicrobial activity, in particular against human coronavirus, influenza virus, other RNA- and DNA-containing viruses and bacteria, having the ability to prevent formation and destroy already formed microbial biofilms.
7 cl, 25 dwg, 4 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIMICROBIAL COMPOSITION FOR FORMING A SPACER | 2019 |
|
RU2707734C1 |
| MUCOSAL INFLUENZA VIRUS VACCINE AND METHOD FOR INFLUENZA PREVENTION | 2004 |
|
RU2390351C2 |
| METHOD OF BONE CAVITIES REPLACEMENT IN TREATMENT OF PATIENTS WITH CHRONIC OSTEOMYELITIS | 2019 |
|
RU2710252C1 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
| NOVEL DERIVATIVES OF POLYOLS, USE THEREOF, A PHARMACEUTICAL COMPOSITION BASED THEREON | 2019 |
|
RU2726119C1 |
| SURGICAL ANTISEPTIC GLUE "ARGACOL" | 2005 |
|
RU2284824C1 |
| POLYMER GEL FOR LOCAL ANTIBACTERIAL THERAPY OF INFECTIOUS COMPLICATIONS OF MUSCULOSKELETAL INJURIES AND SURGERIES AND METHOD FOR ITS PREPARATION | 2023 |
|
RU2822155C1 |
| COMPOSITIONS AND METHODS FOR PROTECTION FROM AIR-SUSPENDED PATHOGENS AND IRRITANTS | 2018 |
|
RU2790223C2 |
| RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
| COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS | 2009 |
|
RU2505306C2 |
